Bliss GVS Pharma Grants Stock Options Under Employee Plan 2019
Bliss GVS Pharma Limited announced the grant of a significant number of stock options under its Employee Stock Options Plan 2019. The decision, made by the company's Nomination and Remuneration Committee on August 12, 2026, allocated 3,20,000 stock options to eligible employees of the company.The stock options are granted under the framework of the Employee Stock Options Plan 2019. The plan covers a total of 3,20,000 equity shares, each having a face value of Re. 1/-.
Details regarding the grant and its associated terms were released today. The exercise price for the options was set at Rs. 43/- per option/per share. This price is based on the BSE Last Closing Market price dated August 11, 2026, after deducting a 91.32% discount, as determined by the Nomination and Remuneration Committee to ensure uniformity with previously granted options.
The stock options are subject to specific vesting conditions and timelines. The vested options must be exercised within six months from the date of their vesting. Furthermore, the equity shares resulting from the exercise of these options will be subject to a lock-in period of six months from the date of allotment.
The grant structure outlines a phased vesting approach for the eligible employees.
Key details of the Employee Stock Options Plan 2019 are summarized below:
| Particulars | Details |
|---|---|
| Total Options Granted | 3,20,000 |
| Options Covered | Re. 1/- each equity shares |
| Exercise Price | Rs. 43/- per option/per share |
| Vesting Schedule | The options will Vest in four installments: 25% after 12 months, 25% after 24 months, 25% after 36 months, and the final 25% after 48 months from the date of grant. |
| Exercise Period | Within 6 months from the date of vesting. |
BLISSGVS Stock Price Movement
Shares of Bliss GVS Pharma Limited slipped by 0.82% on Wednesday, settling at ₹489.55 after trading saw a decline of ₹4.05 from the previous close. The equity recorded a total traded volume of 277,203 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.